85 related articles for article (PubMed ID: 29605512)
21. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
[TBL] [Abstract][Full Text] [Related]
22. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
23. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
24. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
25. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
Alam MS; Choi SU; Lee DU
Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer.
Manu KA; Chai TF; Teh JT; Zhu WL; Casey PJ; Wang M
Mol Cancer Ther; 2017 May; 16(5):914-923. PubMed ID: 28167504
[TBL] [Abstract][Full Text] [Related]
28. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
30. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Liu Y; Wang L; Wu Y; Lv C; Li X; Cao X; Yang M; Feng D; Luo Z
Toxicology; 2013 Feb; 304():120-31. PubMed ID: 23313376
[TBL] [Abstract][Full Text] [Related]
31. Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action.
Ponnusamy S; Lattmann E; Lattmann P; Thiyagarajan T; Padinjarethalakal BN; Narayanan R
Oncol Rep; 2016 Apr; 35(4):2097-106. PubMed ID: 26820391
[TBL] [Abstract][Full Text] [Related]
32. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
[TBL] [Abstract][Full Text] [Related]
33. Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells.
Lee CH; Ying TH; Chiou HL; Hsieh SC; Wen SH; Chou RH; Hsieh YH
Oncotarget; 2017 Jul; 8(29):47425-47439. PubMed ID: 28537893
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
35. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
36. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
Ryu YL; Jung KH; Son MK; Yan HH; Kim SJ; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Oct; 353(1):68-77. PubMed ID: 25016056
[TBL] [Abstract][Full Text] [Related]
37. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
38. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
Xia Y; Lei Q; Zhu Y; Ye T; Wang N; Li G; Shi X; Liu Y; Shao B; Yin T; Zhao L; Wu W; Song X; Xiong Y; Wei Y; Yu L
Cancer Lett; 2014 Dec; 355(2):297-309. PubMed ID: 25301449
[TBL] [Abstract][Full Text] [Related]
39. Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo.
Wang S; Zhang C; Li Y; Li P; Zhang D; Li C
Cancer Chemother Pharmacol; 2019 Mar; 83(3):519-530. PubMed ID: 30542770
[TBL] [Abstract][Full Text] [Related]
40. Licochalcone A-Induced Apoptosis Through the Activation of p38MAPK Pathway Mediated Mitochondrial Pathways of Apoptosis in Human Osteosarcoma Cells In Vitro and In Vivo.
Lin RC; Yang SF; Chiou HL; Hsieh SC; Wen SH; Lu KH; Hsieh YH
Cells; 2019 Nov; 8(11):. PubMed ID: 31739642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]